Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis

Abstract Purpose Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis compared the efficacy and safety of tofacitinib with biologic disease-modifying antirheumatic drugs in patients with RA and a prior inadequate response (IR) to tumor necrosis...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2016-12, Vol.38 (12), p.2628-2641.e5
Hauptverfasser:	Vieira, Maria-Cecilia, PhD, Zwillich, Samuel H., MD, Jansen, Jeroen P., PhD, Smiechowski, Brielan, MSc, Spurden, Dean, PhD, Wallenstein, Gene V., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Abatacept - therapeutic use Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Biological Products - therapeutic use Clinical trials disease-modifying antirheumatic drugs Drug dosages Drug Therapy, Combination Gangrene Humans Internal Medicine Male Medical Education Meta-analysis Methotrexate - therapeutic use Network Meta-Analysis Pharmaceutical industry Piperidines - therapeutic use Pyrimidines - therapeutic use Pyrroles - therapeutic use Quality Rheumatism Rheumatoid arthritis Rituximab - therapeutic use Studies tofacitinib Treatment Failure Treatment Outcome tumor necrosis factor inhibitors Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-TNF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!